Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Crystal Bioscience is a privately-held company that was founded in 2008 to develop a therapeutic antibody discovery engine using chickens. Its platform relies on the large phylogenetic distance between mammals and birds to generate a diverse array of antibodies to human targets that have proven intractable in mammalian and other discovery platforms.

Toray Industries, Inc. (東レ株式会社 Tōre Kabushiki-gaisha) is a multinational corporation headquartered in Japan that specializes in industrial products centered on technologies in organic synthetic chemistry, polymer chemistry, and biochemistry.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Rapid Genomics LLC develops DNA genotyping and data analysis solutions for applications in agriculture, forestry, and livestock industries. Its data analysis solutions include bioinformatics services, such as RNA- sequencing analyses, variant calling, transcriptome assembly, genome assembly, chip-sequencing, and bisulfite- sequencing analysis; and genetic analyses comprising genetic mapping, QTL analysis, genomic selection, association studies, matte-pair allocation, prediction of hybrid values, prediction of genetic gains, heritability estimation, breeding values estimation, and estimation of GxE and genetic correlations. The company was founded by Marcio Resende and Leandro Neves in 2011 and is headquartered in Gainesville, FL.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Central Institute for Experimental Animals (CIEA) (実験動物中央研究所) is a research center for experimental animals in Japan. It was founded by Tatsuji Nomura in 1952 with the mission of improving the level of biomedical research.

Zhaoke Pharmaceutical (Hefei) Co., Ltd., established on 1994-02-07, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug retail;Drug import and export;Disinfectant production(Free of Hazardous Chemicals);Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Disinfectant sales(Free of Hazardous Chemicals);Sales of Class I Medical Devices;Sales of Class II Medical Devices(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

The Chemo-Sero Therapeutic Research Institute operates as a pharmaceutical company specializing in the field of biotechnology, immunology, hematology, and microbiology. It develops and manufactures vaccines and blood plasma products. The firm's products include human and veterinary vaccines, diagnostic antigens, and treatments for congenital disorders. They also provides newborn screening tests and quality assurance systems solutions. The company was founded on December 26, 1945 and is headquartered in Kumamoto, Japan.

Kaneka Corp. engages in the manufacture and sale of chemicals, synthetic resins, and plastics. It operates through the following segments: Material Solutions, Quality of Life Solutions, Health Care Solutions, Nutrition Solutions and Others. The Material Solutions segment covers biodegradable polymers, materials that support the development of social infrastructure and mobility which includes the weight reduction and fuel efficiency improvement. The Quality of Life Solutions segment handles energy saving needs such as housing and living infrastructure, and development of Internet of things (IoT) and artificial intelligence (AI). The Health Care Solutions segment offers solutions through the fusion of devices and medicines, and develops healthcare business based on biopharmaceuticals and regenerative and cellular medicines. The Nutrition Solutions segment provides materials and supplement solutions to food production support in livestock and fishery industries. The Others segment provides agency services for property and life insurance. The company was founded on September 1, 1949 and is headquartered in Osaka, Japan.

Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.

Asahi Breweries Ltd. engages in the manufacture and sale of alcoholic beverages and soft drinks. Its products include beer, whisky and spirits, wine, alcohol -taste beverages, chilled beverages such as tea-based drinks, coffee, carbonated soft drinks, water, fruits and vegetable drinks, lactic acid drinks and others. The company was founded on September 1, 1949 and is headquartered in Tokyo, Japan.

Chiome Bioscience was established in 2005 to commercialize the innovative ADLib® antibody generation technology invented at RIKEN. Since that time the Company has worked on research and development for this system, as well as initiatives for technology licensing. It focused mainly on joint research and contract research with the research arms of pharmaceutical companies and academia. Meanwhile, in 2011 the Company was listed on the Mothers market of the Tokyo Stock Exchange, and in 2015 it merged with LivTech which focused on drug discovery and development of therapeutic antibody for oncology, thus adding drug discovery function. In 2017 the Company went through reorganization of the management team, switching its strategy from platform development to drug discovery and development. At the same time it started setting up the clinical function which enables us to run a clinical study aiming of significant increase in corporate value.